Study summary
The first TED drug consistently reduced eye bulging, double vision and inflammation
4.18times more likely to have a proptosis response than with placebo
What was tested
A pooled analysis of randomized and observational studies of teprotumumab, the first IGF-1R antibody approved for thyroid eye disease (2020).
What they found
- Proptosis response was 4.18 times as likely as with placebo.
- Double vision improvement was 2.29 times as likely.
- Side effects (including hearing changes and high blood sugar) were more common.
What it means
Confirmed IGF-1R blockade as the leading treatment approach.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.